Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06669403

OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

OPT101-100-40 is a multicenter, randomized, placebo-controlled, multiple-ascending-dose, sequential-group, investigator- and participant-blinded, sponsor-unblinded, study of OPT101 vs placebo when administered for up to 4 days to patients admitted to the hospital for treatment of Community Acquired Pneumonia (CAP) with sepsis.

This study will be performed in patients with Community Acquired Pneumonia (CAP) with Sepsis, who are 18 years or older to evaluate the safety and tolerability of OPT101 in a population with elevated levels of pathologic CD40.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Denver Health and Hospital Authority

Denver, Colorado, 80204, United States

Location contact

Ivor S Douglas, MD

PRINCIPAL_INVESTIGATOR

Terra Miller, MSN, RN

CONTACT

[email protected]

303-602-1438

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Are able and willing to give signed informed consent (legally authorized representative can provide informed consent if needed).
  • ≥18 years old;
  • Patients hospitalized for clinically suspected community acquired pneumonia (CAP), defined as the occurrence of (within 48h from hospital admission) at least 1 of the following signs:
  • respiratory rate > 30 breaths/min;
  • fever (> 38.0°C or > 100.4° F);
  • leukopenia (≤ 4,000 WBC/mm3 or leukocytosis (≥ 12,000 WBC/mm3);
  • adults ≥ 70 years of age; altered mental status with no other recognized cause;

AND at least 1 of the following:

  • New onset of purulent sputum or change in character of sputum or increased respiratory secretions;
  • New onset or worsening cough, or dyspnea, or tachypnea;
  • Rales or bronchial breath sounds; AND Radiologic imaging (chest x-ray or CT scan) evidence of pulmonary involvement with new and persistent or progressive and persistent infiltrate, consolidation or cavitation AND SpO2 <92% at room air, or PaO2/FiO2 (or SpO2/FiO2) <300; recorded on one episode
  • Need for non-invasive supplemental oxygen (nasal cannula, simple mask, venturi or reservoir cannula/mask or heated high flow nasal cannula oxygen.
  • Females of child-bearing potential who are sexually active must not wish to get pregnant within 30 days after the end of the study and must be using at least one of the following reliable methods of contraception:
  • Hormonal contraception, systemic, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit until 30 days after the last OPT101 dose
  • A non-hormonal intrauterine device [IUD] or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit until 30 days after the last OPT101 dose
  • A male sexual partner who agrees to use a male condom with spermicide
  • A sterile sexual partner

Exclusion criteria

  • Need for endotracheal intubation and mechanical ventilation or extracorporeal membrane oxygenation (ECMO) at time of study screening
  • QTc ≥ 450 msec on screening ECG
  • Hepatic dysfunction: ALT or AST > 5 ULN; history of chronic hepatic disease (defined with Child-Pugh score ≥ 12)
  • Recent or active hepatitis A infection; test positive or have been treated for hepatitis B, hepatitis C, or HIV infection; evidence of active or untreated latent TB; a recent history of recurrent herpes zoster and/or opportunistic infection; and/or taking immunosuppressant medication.
  • Renal dysfunction: estimated glomerular filtration rate (eGFR) <50 mL/min/1.73 m2, or need for hemodialysis or hemofiltration
  • Current use of >2 immunosuppressive medications or immunosuppression status (AIDS, aplastic anemia, asplenia, systemic chemotherapy within the past 3 months, neutropenia (ANC < local LLN), solid organ or bone marrow transplant recipients)
  • Treatment with prohibited medication within 5 half-lives, and inability to stop during treatment period
  • Anticipated discharge from the hospital or transfer to another hospital within 48 hours of screening
  • Allergy to OPT101or any component of OPT101 formulation
  • Participation in other interventional clinical trials
  • Pregnancy:
  • positive or missing pregnancy test before first drug intake or day 1
  • pregnant or lactating women;
  • Women of childbearing potential and fertile men who do not agree to use at least one primary form of contraception for the duration of the study
  • Current hospital stay >72h
  • Complicated CAP-associated conditions, such as fungal pulmonary infection, tuberculosis infection, abscess, empyema, significant bilateral pleural effusion, massive pulmonary embolism
  • Weight is over 250lbs
  • Any other condition which the Principal Investigator feels may jeopardize the safety of the patient or the objectives of the study. The Principal Investigator should make this determination in consideration of the patient's medical history and current clinical condition.

-

Treatment and study plan

OPT101

Drug

OPT101, is a 15-mer peptide derived from the sequence of mouse CD40L and was designed to target CD40-mediated inflammation. On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.

Placebo

Other

0.9% Sodium Chloride Injection USP, Placebo. On the day of administration, a 50mL IV bag containing saline (0.9% Sodium Chloride Injection USP) which will serve as the placebo will be administered via intravenous (IV) infusion over 120 minutes.

Other names: Placebeo

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: 30 days

    Treatment emergent adverse events will be recorded and assessed by CTCAE v4.0

  2. Incidence of serious adverse events (SAEs)

    Time frame: 30 days

    SAEs will be recorded and assessed by CTCAE v4.0

  3. Incidence of TEAEs leading to study drug discontinuation

    Time frame: 30 days

  4. Incidence and characteristics of presumed infusion reactions

    Time frame: 30 days

    Recorded as an adverse event

Secondary outcomes

  1. To measure the serum pharmacokinetics of OPT101

    Time frame: 30 days

    Serum concentrations of OPT101 to determine AUCO-24

  2. To measure the serum pharmacokinetics of OPT101

    Time frame: 30 days

    Serum concentrations of OPT101 to determine Cmax

  3. To measure the serum pharmacokinetics of OPT101

    Time frame: 30 days

    Serum concentrations of OPT101 to determine Tmax

  4. To measure the serum pharmacokinetics of OPT101

    Time frame: 30 days

    Serum concentrations of OPT101 to determine t1/2

  5. To measure the serum pharmacokinetics of OPT101

    Time frame: 30 days

    Serum concentrations of OPT101 to determine Vz/F

Other outcomes

  1. To observe the changes in degree of sepsis via Pneumonia Severity Index (PSI)

    Time frame: 30 days

    Pneumonia Severity Index (PSI) predicts the need for hospitalization for people with Community Acquired Pneumonia (CAP). Patients are ranked by Risk Class (I , II, III, IV or V). Patients with CAP categorized as Risk Class of I and II can be treated at home. Patients with CAP categorized as Risk Class III may be treated at home or may require a short hospital stay. Patients with CAP categorized as Risk Class of IV and V require hospitalization.

  2. To observe the changes in degree of sepsis via Sequential Organ Failure Assessment (SOFA) score

    Time frame: 30 days

    SOFA grading, minimum value is 0 (normal) and maximum value is 4 (highest degree of dysfunction/failure). The higher the score, the worse the outcome.

  3. To observe the changes in degree of sepsis via Cytokine Release Syndrome (CRS) grading

    Time frame: 30 days

    CRS is graded from Grade 1 to Grade 4. Grade 1 is the best outcome and Grade 4 is the worst outcome in terms of change in degree of sepsis. CRS parameters used for grading include fever, hypotension and hypoxia.

  4. Evaluate Pharmacodynamic Effects of OPT101

    Time frame: 30 days

    Quantitation of Th40 to Treg ratio

  5. Evaluate Pharmacodynamic Effects of OPT101

    Time frame: 30 days

    Quantitation of peripheral blood B cells

  6. Evaluate Pharmacodynamic Effects of OPT101

    Time frame: 30 days

    Quantitation of macrophages

  7. Evaluate Pharmacodynamic Effects of OPT101

    Time frame: 30 days

    Quantitation inflammatory biomarkers

  8. Evaluate Pharmacodynamic Effects of OPT101

    Time frame: 30 days

    Quantitation of Th40 cells,

Study contacts

Contact information is provided by the study sponsor or research team.

Lisa M Boswell, MS

CONTACT

[email protected]

720-315-0198

Marc L Giles, BS

CONTACT

[email protected]

720-315-0198

Sponsors and collaborators

Lead sponsor

Op-T LLC

Industry

Registry information

Official study title

A Phase 1b Study to Assess the Safety, Tolerability and Pharmacokinetics of OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Nov 1, 2024
Registry last updated
Sep 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.